Keryx Biopharmaceuticals, Inc. (KERX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Roth Maintains Keryx (KERX) at 'Buy' Following Q2 Results; Long-Term Study Data Still Looks Good
August 7, 2014 12:05 PM EDTRoth Capital maintains Keryx Biopharmaceuticals (Nasdaq: KERX) at Buy with a target price of $30 following Q2 results.
Analyst Joseph Pantginis noted that Keryx posted Q2 loss of $0.24 per share, versus the firm's loss estimate of $0.19 per share. The analyst commented, We believe the company's commercialization ramp up indicates KERX's strong confidence in a potential U.S. approval for Zerenex. The company has stated plans to launch the product within 12... More
